Academic staff at Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University, Faculty of Science, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Physical Education and Sport, Second Faculty of Medicine
Publications
- Cancer Immunology, Immunotherapy Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)2025 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Non-coding transcriptome profiles in clear-cell renal cell carcinoma2025 | Faculty of Medicine in Pilsen
- European Urology Oncology Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study2025 | Faculty of Medicine in Pilsen
- Cancer Immunology, Immunotherapy First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study2025 | Faculty of Medicine in Pilsen
- Immunotherapy Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations2025 | Faculty of Medicine in Pilsen
- Clinical & Experimental Metastasis Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study2025 | Faculty of Medicine in Pilsen
- In Vivo Prognostic Role of Prostate-specific Antigen Isoforms and Their Early Kinetics in Patients With Metastatic Castration-resistant Prostate Cancer Receiving New Generation Androgen Receptor Targeted Agents2025 | Faculty of Medicine in Pilsen
- Scientific Reports Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab2025 | Faculty of Medicine in Pilsen
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study2024 | First Faculty of Medicine, Faculty of Medicine in Pilsen
Loading network view...
